Clinical Trial

A Study of DS5361b in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-09-17; most recent amendment 2026-05-12.
Trial Details
NCT Number NCT07182591
Lead Sponsor Daiichi Sankyo
Conditions Advanced Solid Tumor
Enrollment 192 participants
Start Date 2025-10-02
Primary Completion 2030-03-18 (estimated)
Study Completion 2030-12-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-14